SCHEDULE 13G: Intracoastal Capital Group Discloses 4.99% Passive Stake in 60 Degrees Pharmaceuticals

A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a 4.99% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., primarily through warrants with blocker provisions.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing beneficial ownership in 60 Degrees Pharmaceuticals, Inc.
• As of February 11, 2025, the Reporting Persons collectively beneficially own 386,792 shares of Common Stock, representing approximately 4.99% of the company's outstanding shares.
• This ownership includes shares issuable upon exercise of Intracoastal Warrant 5.
• The beneficial ownership percentage is capped at 4.99% due to 'blocker provisions' in multiple warrants (Intracoastal Warrant 1, 2, 3, 4, and 5) which prevent exercise if it would result in ownership exceeding this threshold.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 1,263,555 shares immediately following the Securities Purchase Agreement (SPA) on February 5, 2025, and 887,680 shares as of February 11, 2025.
• The shares and warrants were acquired following the execution of a Securities Purchase Agreement (SPA) with the Issuer on February 5, 2025, as disclosed in the Issuer's Form 8-K filed on February 6, 2025.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual regulatory filing disclosing a passive ownership stake. The investment itself could be seen as a positive signal, but the filing's tone is neutral and compliance-focused. The blocker provisions indicate a deliberate choice to remain below the 5% threshold, suggesting a non-activist stance.

Positives

• The investment by Intracoastal Capital LLC and its principals indicates a vote of confidence in 60 Degrees Pharmaceuticals, Inc.
• The passive nature of the investment (below 5% and with blocker provisions) suggests stability and no immediate intent to influence company control.

Negatives

• The blocker provisions in the warrants limit the ability of the Reporting Persons to increase their beneficial ownership beyond 4.99%, potentially restricting their future influence or control over the company.

Risks

• The document highlights the existence of blocker provisions in warrants (Intracoastal Warrant 1, 2, 3, 4, and 5) that prevent the holder from exercising them to the extent that beneficial ownership would exceed 4.99% of the Common Stock. This is a contractual limitation on the investor, not a risk to the company's operations.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future operations or financial performance. It solely focuses on the beneficial ownership disclosure.

Industry Context

This filing is a standard regulatory disclosure of a significant, yet passive, ownership stake by an investment group in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis, but rather details a specific investment transaction.

Related Party Transactions

• The Securities Purchase Agreement (SPA) between 60 Degrees Pharmaceuticals, Inc. and Intracoastal Capital LLC, which led to the issuance of shares and warrants, constitutes a transaction between the issuer and a significant investor.

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor, even a passive one, can influence market perception and potentially share price. The issuance of new shares and warrants as part of the SPA could lead to dilution for existing shareholders.

Key Dates

Keywords

Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Warrants, Intracoastal Capital LLC, 60 Degrees Pharmaceuticals, Passive Investment, Securities Purchase Agreement, Equity Stake